Published by Coherent Market Insights
Posted on September 28, 2021
PD-1 and PDL-1 Inhibitors Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of PD-1 and PDL-1 Inhibitors Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/173
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Pfizer, Inc., Bristol-Myers Squibb, Merck KGaA, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, and Ono Pharmaceutical Co., Ltd.
PD-1 and PDL-1 inhibitors are a group of checkpoint inhibitors that are being developed for the treatment of cancer. Targeted cancer therapy is the primary objective of extensive research related to cancer drugs. Immune cells in humans are programmed to attack the foreign cell on activation. PD-1 and PDL-1 are among those activation points present on the immune cells. Sometimes cancer cells also use this PD-1 and PDL-1 trigger points to avoid being attacked by the immune cells. Therefore, cancer drugs targeting these cells hold tremendous potential in the cancer treatment market. Approved PD-1 and PDL-1 inhibitor drugs have become blockbuster products. The global PD-1 and PDL-1 inhibitors market is segmented based on the drug type and application as follows:
Drug Type
PD-1 inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
PDL-1 inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Applications
Non-small cell lung cancer
Kidney cancer
Melanoma of the skin
Bladder cancer
Merkel cell skin cancer
Others
PD-1 inhibitors are effective in treating different types of chronic disease such as non-small-cell lung carcinoma (NSCLC), kidney cancer, melanoma of the skin, head and neck cancers, bladder cancer, and Hodgkin lymphoma. Opdivo is leading the race with US$ 3.8 Bn in sales in 2016, compared to US$ 1.4 Bn of Keytruda in 2016. Both these drugs have witnessed significant development in past two years with respect to extended therapeutic application and approvals in European countries and Japan.
PDL-1 inhibitors are proven to be effective in NSCLC, bladder cancer, and Merkel cell skin cancer. In March 2017, Avelumab received the U.S. Food and Drug Administration (FDA) approval for metastatic Merkel cell carcinoma (MCC), a rare skin cancer with no approved therapies. The drug therefore, received approval under the accelerated approval process, requiring the developers, Pfizer, Inc. and Merck KGaA to conduct larger clinical trials to establish complete safety and efficacy of the drug. The drug is also being tested for bladder cancer, NSCLC, gastric cancer, ovarian cancer, and renal cancer, under the JAVELIN clinical trial program. Extended therapeutic applications widens the potential opportunity for the drugs in the global PD-1 inhibitors and PDL-1 inhibitors market.
Active research activities to spur the global PD-1 and PDL-1 inhibitors market growth
Increasing research and development activities in cancer treatment is expected to drive growth of the global PD-1 and PDL-1 inhibitors market during the forecast period. PD-1 and PDL-1 biomarkers are also called immune checkpoints. Trails from Merck & Co. and Bristol-Myers Squibb have shown PD-1 and PDL-1 inhibitors to be efficient in patients expressing higher level of PD-1 and PDL-1 biomarkers, restricting the potential market to only these patients. Therefore, all of the big pharma companies in the global market of PD-1 and PDL-1 inhibitors are combining the PD-1 and PDL-1 inhibitors with other targeted cancer drugs to cater to a larger set of population. The global PD-1 and PDL-1 inhibitors market is poised to grow significantly with more product developments in the segment. There are 65 clinical studies in phase 2 and phase 3 phase globally. Commercialization of a novel drug in this segment would be a great booster for the growth for the global PD-1 and PDL-1 inhibitors market.
Regional Insights
A major share of the revenue of the global PD-1 and PDL-1 inhibitors market is currently concentrated in North America, Europe, and Japan as these are the three major revenue generating nations with high insurance coverage, high healthcare investment, and are highly developed pharmaceutical markets. The market players would be eyeing other regions for tapping the cancer treatment market opportunities in those regions. Uncertain regulations challenging the sales of patented pharmaceutical products has been a major deterring factor for global pharmaceutical companies to enter into emerging economies. However, novel rugs for cancer type with no treatment available currently would find positive outlook in these regions, though the high pricing would inhibit their sales in emerging economies.
Key Developments
Research and development activities related to PD-1 and PDL-1 inhibitors is expected to boost the market growth. For instance, in March 2018, researchers from University Hospital Carl Gustav Carus, Germany, observed that the expression of the inhibitory immune checkpoints PD-L1 and VISTA may explain the poor responsiveness of prostate cancer patients to cytotoxic T lymphocyte antigen-4 blockade and supports the design of a combination therapy targeting both molecules.
In May 3, 2019, researchers from Shin-Kong Wu Ho-Su Memorial Hospital reported that PD-1 inhibitors show anti-tumor effects on advanced malignancies, including metastatic melanoma, advanced cutaneous squamous cell carcinoma, urothelial tumors, and duodenal adenocarcinoma in renal transplant patients.
In August 2019, researchers from Jagiellonian University, Poland, used well-known in vitro methods and revealed that there is no direct binding between CA-170 – the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins and PD-L1.
Buy This Premium Report Of PD-1 and PDL-1 Inhibitors Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/173
In this study, the years considered to estimate the market size of PD-1 and PDL-1 Inhibitors are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of PD-1 and PDL-1 Inhibitors Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of PD-1 and PDL-1 Inhibitors Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post PD-1 and PDL-1 Inhibitors Market Report 2021-2028 : Recent Study Including Regional Analysis, Applications, Growth Factors And Key Players appeared first on Gatorledger.
PD-1 and PDL-1 Inhibitors Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of PD-1 and PDL-1 Inhibitors Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/173
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Pfizer, Inc., Bristol-Myers Squibb, Merck KGaA, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, and Ono Pharmaceutical Co., Ltd.
PD-1 and PDL-1 inhibitors are a group of checkpoint inhibitors that are being developed for the treatment of cancer. Targeted cancer therapy is the primary objective of extensive research related to cancer drugs. Immune cells in humans are programmed to attack the foreign cell on activation. PD-1 and PDL-1 are among those activation points present on the immune cells. Sometimes cancer cells also use this PD-1 and PDL-1 trigger points to avoid being attacked by the immune cells. Therefore, cancer drugs targeting these cells hold tremendous potential in the cancer treatment market. Approved PD-1 and PDL-1 inhibitor drugs have become blockbuster products. The global PD-1 and PDL-1 inhibitors market is segmented based on the drug type and application as follows:
Drug Type
PD-1 inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
PDL-1 inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Applications
Non-small cell lung cancer
Kidney cancer
Melanoma of the skin
Bladder cancer
Merkel cell skin cancer
Others
PD-1 inhibitors are effective in treating different types of chronic disease such as non-small-cell lung carcinoma (NSCLC), kidney cancer, melanoma of the skin, head and neck cancers, bladder cancer, and Hodgkin lymphoma. Opdivo is leading the race with US$ 3.8 Bn in sales in 2016, compared to US$ 1.4 Bn of Keytruda in 2016. Both these drugs have witnessed significant development in past two years with respect to extended therapeutic application and approvals in European countries and Japan.
PDL-1 inhibitors are proven to be effective in NSCLC, bladder cancer, and Merkel cell skin cancer. In March 2017, Avelumab received the U.S. Food and Drug Administration (FDA) approval for metastatic Merkel cell carcinoma (MCC), a rare skin cancer with no approved therapies. The drug therefore, received approval under the accelerated approval process, requiring the developers, Pfizer, Inc. and Merck KGaA to conduct larger clinical trials to establish complete safety and efficacy of the drug. The drug is also being tested for bladder cancer, NSCLC, gastric cancer, ovarian cancer, and renal cancer, under the JAVELIN clinical trial program. Extended therapeutic applications widens the potential opportunity for the drugs in the global PD-1 inhibitors and PDL-1 inhibitors market.
Active research activities to spur the global PD-1 and PDL-1 inhibitors market growth
Increasing research and development activities in cancer treatment is expected to drive growth of the global PD-1 and PDL-1 inhibitors market during the forecast period. PD-1 and PDL-1 biomarkers are also called immune checkpoints. Trails from Merck & Co. and Bristol-Myers Squibb have shown PD-1 and PDL-1 inhibitors to be efficient in patients expressing higher level of PD-1 and PDL-1 biomarkers, restricting the potential market to only these patients. Therefore, all of the big pharma companies in the global market of PD-1 and PDL-1 inhibitors are combining the PD-1 and PDL-1 inhibitors with other targeted cancer drugs to cater to a larger set of population. The global PD-1 and PDL-1 inhibitors market is poised to grow significantly with more product developments in the segment. There are 65 clinical studies in phase 2 and phase 3 phase globally. Commercialization of a novel drug in this segment would be a great booster for the growth for the global PD-1 and PDL-1 inhibitors market.
Regional Insights
A major share of the revenue of the global PD-1 and PDL-1 inhibitors market is currently concentrated in North America, Europe, and Japan as these are the three major revenue generating nations with high insurance coverage, high healthcare investment, and are highly developed pharmaceutical markets. The market players would be eyeing other regions for tapping the cancer treatment market opportunities in those regions. Uncertain regulations challenging the sales of patented pharmaceutical products has been a major deterring factor for global pharmaceutical companies to enter into emerging economies. However, novel rugs for cancer type with no treatment available currently would find positive outlook in these regions, though the high pricing would inhibit their sales in emerging economies.
Key Developments
Research and development activities related to PD-1 and PDL-1 inhibitors is expected to boost the market growth. For instance, in March 2018, researchers from University Hospital Carl Gustav Carus, Germany, observed that the expression of the inhibitory immune checkpoints PD-L1 and VISTA may explain the poor responsiveness of prostate cancer patients to cytotoxic T lymphocyte antigen-4 blockade and supports the design of a combination therapy targeting both molecules.
In May 3, 2019, researchers from Shin-Kong Wu Ho-Su Memorial Hospital reported that PD-1 inhibitors show anti-tumor effects on advanced malignancies, including metastatic melanoma, advanced cutaneous squamous cell carcinoma, urothelial tumors, and duodenal adenocarcinoma in renal transplant patients.
In August 2019, researchers from Jagiellonian University, Poland, used well-known in vitro methods and revealed that there is no direct binding between CA-170 – the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins and PD-L1.
Buy This Premium Report Of PD-1 and PDL-1 Inhibitors Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/173
In this study, the years considered to estimate the market size of PD-1 and PDL-1 Inhibitors are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of PD-1 and PDL-1 Inhibitors Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of PD-1 and PDL-1 Inhibitors Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post PD-1 and PDL-1 Inhibitors Market Report 2021-2028 : Recent Study Including Regional Analysis, Applications, Growth Factors And Key Players appeared first on Gatorledger.
Explore more articles in the Research Reports category
